A continuous glucose monitoring system, or CGM, is a wearable device that estimates glucose every few minutes and shows trends over time. CGMs are most proven for people with diabetes, especially those using insulin, but some adults use them to understand food, exercise, and medication effects. Readings can be useful, but they are not perfect.
Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →What is a continuous glucose monitoring system?
A continuous glucose monitoring system is a small wearable sensor system that estimates glucose around the clock. Most systems update about every few minutes, then send numbers, arrows, and alerts to an app, receiver, or connected device 1.
What a CGM measures: interstitial glucose, not direct blood glucose
A CGM measures glucose in interstitial fluid, the fluid between your cells. That value usually tracks blood glucose, but it can lag behind during fast changes, such as after a meal, exercise, or insulin use 1.
That lag is one reason a CGM is best understood as a pattern tool, not a perfect lab test. It can help you see direction: rising, falling, or staying steady.
The main parts: sensor, transmitter, app or receiver
Most CGMs use a disposable sensor worn on the skin, often on the arm or abdomen. Some have a transmitter that sends data to a smartphone app or receiver; some combine these parts into one unit 1.
How CGM differs from a finger-stick glucose meter
A blood glucose meter checks a drop of blood at one moment in time. CGM gives many readings across the day and night, which can show patterns that self-monitored blood glucose may miss 2.
| Feature | CGM | Finger-stick blood glucose meter |
|---|---|---|
| What it measures | Interstitial glucose estimate | Capillary blood glucose |
| Data style | Frequent readings, trend arrows, alerts | Single point-in-time value |
| Best use | Patterns, time in range, overnight lows, insulin decisions when cleared and clinically appropriate | Confirming readings, checking symptoms, backup testing |
| Main limit | Lag time, sensor errors, alarms, skin irritation | Fewer data points and no trend line |
What should you know before using a CGM?
CGM data can be helpful, but it works best when you know what the numbers mean and when not to overreact. Before using one for 14 days or longer, ask how the data will change your care plan, if at all.
Who benefits most from a CGM?
CGMs are most useful when glucose data can guide clear decisions. The strongest use case is diabetes care, especially when insulin, hypoglycemia risk, or time in range matters 2.
People with type 1 diabetes
For type 1 diabetes, CGM helps detect highs, lows, overnight changes, and fast glucose shifts. Endotext describes automated insulin delivery, which links CGM data with algorithm-guided insulin dosing, as a widely available and preferred insulin delivery method in type 1 diabetes 2.
People with type 2 diabetes using insulin
People with type 2 diabetes who use insulin may benefit because CGM can reveal glucose patterns between finger sticks. In a randomized clinical trial of adults with type 2 diabetes treated with basal insulin, CGM improved glycemic control compared with blood glucose meter monitoring 3.
People with gestational diabetes or pregnancy-related glucose concerns
Pregnancy changes glucose needs quickly, so monitoring should be managed with an obstetric or diabetes care team. A randomized trial studied real-time CGM in pregnancies with gestational diabetes, but pregnancy care should not be self-managed from CGM data alone 5.
People with prediabetes, metabolic syndrome, or weight-loss goals
For people without diagnosed diabetes, CGM may be an education tool. It can show how meals, sleep, stress, and activity relate to glucose, but it cannot diagnose prediabetes, metabolic syndrome, or diabetes by itself. If your main goal is metabolic health, start with standard labs and a clinician-reviewed plan; our guides to normal blood sugar levels, weight loss for prediabetes, and metabolic syndrome and weight loss explain what those numbers can mean.
What does the evidence show for CGM in type 2 diabetes?
Type 2 diabetes evidence is growing, but the answer depends on the treatment plan. CGM is best supported for people using insulin, while newer trials are testing whether CGM can guide food choices and self-care in people not taking insulin.
Findings from randomized trials in people using basal insulin
In a 2021 JAMA randomized clinical trial, adults with type 2 diabetes treated with basal insulin used CGM or blood glucose meter monitoring. The CGM group had better glycemic control than the meter group during the study, though individual results varied 3.
Findings from randomized trials in people not taking insulin
A 2025 randomized trial studied CGM to guide food choices and diabetes self-care in people with type 2 diabetes who were not taking insulin. The key point for patients is scope: this evidence applies to that studied group, not to every wellness user buying a glucose biosensor 4.
What outcomes matter: A1C, time in range, hypoglycemia, and behavior change
A1C is a lab estimate of average glucose over about 2 to 3 months. CGM adds different information: time in range, time below range, glucose variability, and glucose management indicator, which can help clinicians see patterns that A1C alone may miss 2.
Benefits should be weighed against downsides. CGM can create false alarms, missing data, skin irritation, and stress from watching every number. It is most helpful when the data leads to a clear, safe action plan.
Can you just buy a continuous glucose monitor?
Access to CGM depends on the device type. Some CGMs are prescription medical devices, while some over-the-counter glucose biosensors are marketed for adults who are not using insulin.
Prescription CGMs vs over-the-counter glucose biosensors
Prescription CGMs include systems used in diabetes care, such as Dexcom G6, Dexcom G7, Abbott FreeStyle Libre 2, Abbott FreeStyle Libre 3, and Medtronic Guardian systems. Over-the-counter glucose biosensors, such as Dexcom Stelo, may be easier to buy but are not the same as a clinician-managed diabetes plan.
Why diabetes treatment decisions should involve a clinician
Glucose decisions can become risky when insulin, sulfonylureas, pregnancy, kidney disease, or hypoglycemia symptoms are involved. CGM readings should not be used to change medication without a qualified clinician, because the wrong change can raise the risk of hypoglycemia or hyperglycemia.
What to ask before buying a lower-cost or non-iCGM device
Ask whether the device is FDA-cleared, whether it is an integrated continuous glucose monitor, whether it can be used for treatment decisions, and whether finger-stick confirmation is required. A review of iCGM systems notes that non-iCGM devices should not be assumed to have the same performance standards as FDA-cleared iCGMs 9.
How much does a CGM device cost?
CGM cost varies a lot because sensors, transmitters, apps, receivers, pharmacy benefits, and insurance rules differ. The real monthly cost may depend on sensor wear time, coverage, copays, and whether your plan requires prior authorization.
Why monthly cost varies by brand, sensor duration, insurance, and pharmacy benefit
A CGM may have separate costs for sensors and a receiver, though many systems use a phone app. Sensor life also matters: replacing a sensor every 10 days has a different monthly cost than replacing one every 14 or 15 days.
What to check with insurance or Medicare before starting
- Is the CGM covered under pharmacy benefits or durable medical equipment?
- Do I need a prescription, prior authorization, or proof of insulin use?
- Which brands are preferred on my plan?
- What is the monthly cost for sensors, transmitters, and receivers?
- What happens if a sensor fails early?
Why the cheapest device is not always the best fit
A lower-cost sensor may be fine for learning broad glucose patterns. But if you use insulin or need alarms, data sharing, or treatment-decision support, device performance and FDA clearance matter more than the sticker price 9.
What are the downsides of using a CGM?
CGM downsides are usually practical, not dramatic. The main issues are accuracy limits, lag time, alarms, missing data, skin irritation, and data overload.
Sensor accuracy limits and lag time
FDA-cleared iCGMs must meet defined performance requirements, but no CGM is perfect. One analysis notes that even devices meeting minimum requirements can still produce some readings that differ from blood glucose enough to matter 8.
False alarms, missing data, and skin irritation
Alarms can wake you or interrupt work. Sensors can fall off, lose signal, or irritate the skin. NIDDK also notes that users may have issues with the sensor site or need help learning how to use the device 1.
Data overload and anxiety
For some people, constant glucose data is motivating. For others, it can create worry or rigid food rules. If CGM makes eating feel fearful or obsessive, it is worth stepping back and reviewing the data with a clinician.
When symptoms and CGM readings do not match
If you feel shaky, confused, sweaty, faint, very thirsty, or very ill, do not ignore symptoms because a sensor looks normal. Confirm with a blood glucose meter when appropriate and follow your clinician’s safety plan.
How do FDA-cleared iCGM systems compare with other CGM devices?
iCGM means integrated continuous glucose monitor. These systems meet FDA special controls for accuracy, reliability, and safe integration with other devices, such as insulin pumps or automated insulin delivery systems 9.
What iCGM means
An integrated continuous glucose monitor can communicate with other compatible diabetes devices. This is important for automated insulin delivery, where sensor data helps an algorithm guide insulin delivery 6.
Nonadjunctive vs adjunctive CGM use
Nonadjunctive means the CGM can be used for certain diabetes treatment decisions without routine finger-stick confirmation, when used as directed. Adjunctive means a finger-stick blood glucose value is still needed before making treatment decisions 9.
| Option | What it is | Best fit | Main caution |
|---|---|---|---|
| Prescription CGM | Clinician-prescribed CGM used for diabetes care | People with diabetes, especially insulin use or hypoglycemia risk | Coverage rules, training, and confirmatory meter checks may still apply |
| OTC glucose biosensor | Non-prescription sensor for glucose insights | Adults seeking pattern awareness, usually outside insulin-treated diabetes | Not a diagnosis tool and not a substitute for diabetes care |
| Professional CGM | Short-term sensor placed or prescribed by a clinic for review | Clinician-guided pattern assessment | You may not see real-time numbers depending on setup |
| Finger-stick meter | Blood glucose meter using a drop of blood | Confirmation, backup testing, low-cost spot checks | No continuous trend line or overnight pattern view |
How can CGM insights fit with weight-loss care at Chia?
Chia does not sell CGM devices. We do care for patients with weight and metabolic health goals, where CGM data can sometimes be a useful education tool alongside labs, symptoms, medication history, and clinician review.
If CGM shows repeated high post-meal glucose or wide glucose swings, that is not a diagnosis by itself. It can be a reason to ask about standard testing, such as fasting glucose and A1C, and to review nutrition, sleep, activity, medications, and weight history. For background, see our guides to weight loss and diabetes and food noise and GLP-1 science.
For some adults with excess weight, prediabetes, or metabolic risk, prescription weight-loss care may fit after clinical review. At Chia, we offer compounded semaglutide injection and compounded tirzepatide tablets or injections when clinically appropriate. Ozempic and Wegovy are brand names for semaglutide, a GLP-1 receptor agonist; Mounjaro and Zepbound are brand names for tirzepatide, a dual GIP/GLP-1 receptor agonist 10 11. Compounded formulations are not FDA-approved and do not have FDA-evaluated outcomes data.
GLP-1 and GIP/GLP-1 medicines can lower appetite and affect glucose, so safety matters 10 11. People with diabetes, hypoglycemia risk, pregnancy, insulin use, or sulfonylurea use should discuss weight-loss medication with a licensed clinician. Common side effects for GLP-1 class medicines include nausea, vomiting, diarrhea, constipation, and abdominal discomfort; some people should not use them based on medical history 10 11.
| Chia option | Forms in Chia catalog | Current starting price | Where it may fit |
|---|---|---|---|
| Semaglutide | Compounded injection; microdosing plans available; compounded formulations are not FDA-approved | Plans currently start at $249/mo | Clinician-reviewed weight care when appropriate |
| Tirzepatide | Compounded tablets or injection; microdosing plans available; compounded formulations are not FDA-approved | Tablets currently start at $249/mo; injections currently start at $299/mo | Clinician-reviewed weight care when appropriate |
| Weight + Energy protocol | NAD+ injection + choice of compounded GLP-1; compounded formulations are not FDA-approved | Plans currently start at $309/mo | For eligible patients whose clinician agrees this protocol fits their goals |
Treatment at Chia is 100% online: a short health questionnaire, then a licensed US provider reviews your history and prescribes only where clinically appropriate. Medications are compounded in the US by state-licensed 503A compounding pharmacies and shipped to your door. Dosing is provider-guided and adjusted over time, including microdosing plans where appropriate, and patients can message the care team through the portal.
3-min quiz
Want clinician-reviewed weight care?
Chia does not offer CGM devices, but if your CGM patterns raise questions about weight, prediabetes, or metabolic risk, you can start an online evaluation for Chia’s semaglutide, tirzepatide, or Weight + Energy options. A prescription requires a medical evaluation and is not guaranteed. Compounded drugs are not FDA-approved.
What should you ask a clinician before starting a CGM?
Before starting CGM, ask what question you are trying to answer. A useful CGM plan should define what readings matter, when to confirm with a meter, and how often your care team will review the data.
- Do I have diabetes, prediabetes, hypoglycemia risk, or another clear reason to monitor?
- Which readings should prompt urgent care or a same-day call?
- Should I confirm low, high, or unexpected readings with a blood glucose meter?
- What is my target range, and does it differ during pregnancy, illness, exercise, or sleep?
- How should I share CGM reports with my care team?
- Will CGM data change my nutrition, activity, or medication plan?
- Could alarms or constant data increase anxiety for me?
FDA guidance also recognizes CGM data as an important data type in drug and biologic clinical trials, but that technical guidance does not mean CGM replaces clinical diagnosis or standard lab testing 7.
Which next step fits which person?
The right next step depends on why you want glucose data. CGM is most useful when it answers a specific question and the result changes a care plan within days to weeks, not when it creates numbers with no plan.
| Your situation | Sensible next step | Why |
|---|---|---|
| You have type 1 diabetes | Ask your diabetes care team about prescription CGM and automated insulin delivery options | CGM is central to modern insulin management and hypoglycemia prevention |
| You have type 2 diabetes and use insulin | Ask whether prescription CGM is appropriate and covered | Randomized evidence supports improved glycemic control in basal-insulin users |
| You are pregnant or have gestational diabetes | Work with your obstetric or diabetes team | Pregnancy glucose targets and treatment decisions need close clinician oversight |
| You have prediabetes or metabolic syndrome | Start with labs, lifestyle care, and clinician review; CGM may be an education tool | CGM patterns can inform behavior, but diagnosis comes from clinical testing |
| You want weight-loss care and glucose insight | Discuss labs, weight history, medications, and goals with a licensed clinician | For some people, weight loss can support glucose health; medication fit depends on review |
| You have low-glucose symptoms | Do not self-diagnose from CGM; seek medical evaluation | Symptoms and sensor readings need safe confirmation and context |
When should you get help now?
Urgent symptoms matter more than a single sensor number. Get medical help now if you have confusion, fainting, seizure, chest pain, severe vomiting, trouble breathing, signs of dehydration, or symptoms of very low glucose that do not improve.
If your CGM says glucose is very low but you feel well, confirm with a blood glucose meter if you have one and follow your clinician’s plan. If your CGM says glucose is very high and you feel ill, especially with vomiting, abdominal pain, deep breathing, or confusion, seek urgent care.
3-min quiz
Start with a clinical review, not just a number
If your glucose patterns are part of a bigger weight or metabolic health goal, Chia can help you explore clinician-reviewed care online. You can also ask an AI agent to use DoctorMCP at mcp.chia.health to start the same eligibility path. A prescription requires a medical evaluation and is not guaranteed.
FAQ: continuous glucose monitoring systems
Some over-the-counter glucose biosensors are available without a prescription, but many CGMs used for diabetes care still require a prescription. If you use insulin, are pregnant, have diabetes, or have low-glucose symptoms, involve a clinician before relying on CGM data.
Sometimes, but not always. Some FDA-cleared systems can be used for certain treatment decisions when used as directed. You may still need a finger-stick meter when symptoms do not match the CGM reading, readings are changing fast, or the device or clinician tells you to confirm.
No. A CGM can show glucose patterns, but diabetes and prediabetes are diagnosed through clinical evaluation and lab testing, such as fasting glucose, A1C, or an oral glucose tolerance test when appropriate.
A CGM may help some people see how meals, sleep, stress, and activity relate to glucose. It does not cause weight loss by itself. For some people with excess weight or metabolic risk, a clinician-reviewed plan may include nutrition, activity, sleep care, and sometimes medication. Compounded GLP-1 medications are not FDA-approved, and results are not established for compounded formulations.
Many people can use a CGM while taking a GLP-1 medication, but the reason matters. People with diabetes, insulin use, sulfonylurea use, pregnancy, or hypoglycemia symptoms should discuss CGM and medication plans with a clinician.
Time in range is the percent of time your glucose stays within a target range set by your care team. It can show daily glucose control in a way A1C cannot, including overnight lows and post-meal highs.
If you have symptoms of low glucose, follow your clinician’s low-glucose plan and seek urgent help if symptoms are severe or do not improve. If the number seems wrong or you feel fine, confirm with a blood glucose meter if available.
CGMs are used in some pregnancy-related glucose care, including gestational diabetes, but pregnancy monitoring should be managed with an obstetric or diabetes care team. Do not change food intake, insulin, or other medication based only on CGM readings without clinical guidance.
References
- 1.National Institute of Diabetes and Digestive and Kidney Diseases. Continuous Glucose Monitoring. NIDDK, accessed 2026.
- 2.Feingold KR, Adler RA, Ahmed SF, et al., editors. Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control. Endotext, 2024.
- 3.Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021.
- 4.Martens TW, Willis HJ, Bergenstal RM, et al. A Randomized Controlled Trial Using Continuous Glucose Monitoring to Guide Food Choices and Diabetes Self-Care in People with Type 2 Diabetes not Taking Insulin. Diabetes Technology & Therapeutics. 2025.
- 5.Valent AM, Rickert M, Pagan CH, et al. Real-Time Continuous Glucose Monitoring in Pregnancies With Gestational Diabetes Mellitus: A Randomized Controlled Trial. Diabetes Care. 2025.
- 6.Kudva YC, Raghinaru D, Lum JW, et al. A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes. The New England Journal of Medicine. 2025.
- 7.U.S. Food and Drug Administration. Submitting Continuous Glucose Monitoring Data in Clinical Trials. FDA Guidance Document. 2026.
- 8.Kovatchev BP. Minimum requirements for continuous glucose monitors. Journal of Diabetes Science and Technology. 2025.
- 9.Heinemann L, Freckmann G, Ehrmann D, et al. Importance of FDA-Integrated Continuous Glucose Monitors to Diabetes Care. Journal of Diabetes Science and Technology. 2024.
- 10.U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. FDA label, accessed 2026.
- 11.U.S. Food and Drug Administration. Zepbound (tirzepatide) injection prescribing information. FDA label, accessed 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
